Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Chugai Pharmaceutical Co ( (JP:4519) ) is now available.
Chugai Pharmaceutical announced that Eli Lilly reported positive topline Phase 3 data from the ATTAIN-MAINTAIN trial of orforglipron, an oral GLP-1 drug originally discovered by Chugai and licensed exclusively to Lilly for development and commercialization. In the trial, orforglipron met its primary and all key secondary endpoints for weight maintenance versus placebo over 52 weeks following prior weight loss on Wegovy or Zepbound, with participants switching from Wegovy maintaining nearly all their weight reduction, and Lilly has submitted the drug to the U.S. Food and Drug Administration for obesity treatment, underscoring the potential commercial and strategic value of Chugai’s discovery in the growing obesity therapeutics market.
The most recent analyst rating on (JP:4519) stock is a Buy with a Yen9169.00 price target. To see the full list of analyst forecasts on Chugai Pharmaceutical Co stock, see the JP:4519 Stock Forecast page.
More about Chugai Pharmaceutical Co
Chugai Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company listed on the Prime Market of the Tokyo Stock Exchange, specializing in the research, development, and commercialization of innovative prescription drugs. The company operates globally through partnerships with major international pharma companies, focusing on advanced therapies and novel molecules discovered in-house and out-licensed to partners for worldwide development and commercialization.
Average Trading Volume: 2,903,603
Technical Sentiment Signal: Buy
Current Market Cap: Yen13596.4B
For an in-depth examination of 4519 stock, go to TipRanks’ Overview page.